As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort

Asthma is a chronic inflammatory airway disease with variable airway obstruction as well as bronchial hyperreactivity [1]. With a 12-month prevalence between 1,8 % and 6,4 % asthma causes high economic burden in Germany [2, 3]. The German Asthma Net (GAN), a non-profit organisation was founded in 2009 with the aim of establishing a central, prospective patient registry to contribute to research and public health in the field of severe bronchial asthma (GINA stages IV and V). Up to end of December 2022, data from 3504 patients has been entailed which represents the comprehensive cohort of patients with severe asthma in German-speaking countries. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflicts of interest: CAH has nothing to disclose. Conflicts of interest: RB reports grants to Mainz University from Boehringer Ingelheim, GSK, Novartis, and Roche, as well as personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Cipla, GSK, Novartis, Roche, Sanofi, and Teva, all outside the submitted work. Conflicts of interest: HS reports fees for lectures or consultations from Astrazeneca, GSK, Novartis, Sanofi all outside the submitted work. Conflicts of interest: CT has nothing to disclose. Conflicts of interest: DS reports fees for lectures or consultations from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Janssen, MSD, Sanofi, all outside the submitted work. Conflicts of interest: KM reports fees for lectures or consultations from Astrazeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi all outside the submitted work. Conflicts of interest: CS reports fees for lectures or consultations from AstraZeneca, Novartis and Sanofi, all outside the submitted work. Conflicts of interest: OS reports fees for lectures or consultations from Astrazeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi all outside the submitted work. Conflicts of interest: SK has received fees for lectures and/or advisory board meetings from AstraZeneca, Chiesi, GSK, Novartis, Roche, Sanofi Aventis and Teva, all outside the submitted work. Conflicts of interest: MJ has nothing to disclose. Conflicts of interest: MI has received fees for lectures and/or advisory board meetings from Alk Pharma, AstraZeneca, Berlin-Chemie, Chiesi, CSL-Berhing, Jansen&Jansen, Menarini, Novartis, Roche, Sanofi Aventis and Teva, all outside the submitted work. Conflicts of interest: TW and/or his institution received grants advisory/lecture/clinical trial fees and non- financial support BMBF (German Ministry of Research and Education), AstraZeneca, GSK, Sanofi Aventis and Biotest outside the submitted work. Conflicts of interest: RE has nothing to disclose. Conflicts of interest: EH is funded by the German Ministry of Education and Research (BMBF) (CHAMP, Project Number: 01GL1742D) for characterisation of children and adolescents with severe asthma. He reports personal fees from ALK, Boehringer Ingelheim, GSK, Leti Pharma, Novartis, Nutricia, Sanofi, and Stallergenes all outside the submitted work